POLE and metastatic neoplasm: Similarly, our data showed that 16.9% of pancreatic cancer patients had DDR pathway alterations, with actionable mutations such as BRCA2, and POLE. However, our study showed no significant difference in the regulatory pathways affected in primary and metastatic tumors.